Cargando…
Pravastatin reduces plasma levels of extracellular vesicles in pregnancies at high risk of term preeclampsia
Introduction: Elevated plasma levels of extracellular vesicles have been associated with impaired placentation, angiogenesis imbalance, intravascular inflammation, and endothelial dysfunction in women with preeclampsia, thus suggesting that circulating vesicles may be a good therapeutic target for t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323224/ https://www.ncbi.nlm.nih.gov/pubmed/37426825 http://dx.doi.org/10.3389/fphar.2023.1166123 |
_version_ | 1785068923371126784 |
---|---|
author | Santoyo, Jean Michell Noguera, José Antonio Avilés, Francisco Hernández-Caselles, Trinidad de Paco-Matallana, Catalina Delgado, Juan Luis Cuevas, Santiago Llinás, M. Teresa Hernández, Isabel |
author_facet | Santoyo, Jean Michell Noguera, José Antonio Avilés, Francisco Hernández-Caselles, Trinidad de Paco-Matallana, Catalina Delgado, Juan Luis Cuevas, Santiago Llinás, M. Teresa Hernández, Isabel |
author_sort | Santoyo, Jean Michell |
collection | PubMed |
description | Introduction: Elevated plasma levels of extracellular vesicles have been associated with impaired placentation, angiogenesis imbalance, intravascular inflammation, and endothelial dysfunction in women with preeclampsia, thus suggesting that circulating vesicles may be a good therapeutic target for the treatment of the disease. Recently, statins have been considered a potential treatment for the prevention of preeclampsia because of their pleiotropic effects, including the improvement of endothelial dysfunction and inhibition of inflammatory responses. However, the effects of these drugs on circulating vesicles concentration in women at risk of preeclampsia have not been established. Herein, we aimed to assess the effects of pravastatin on circulating extracellular vesicle generation in women at high risk of term preeclampsia. Methods: In a sample of 68 singleton pregnant women participating in the multicenter, double-blind, placebo-controlled STATIN trial (Nº EducraCT 2016-005206-19 ISRCTN), 35 women received a placebo and 33 women received a 20 mg/day dose of pravastatin for approximately 3 weeks (from 35 to 37 weeks of gestation until delivery). Large extracellular vesicles were characterized and quantified by flow cytometry using annexin V and cell-specific antibodies directed against platelet, endothelial, leukocyte, and syncytiotrophoblast cell surface markers. Results: In women who received the placebo, a significant increase in the plasma levels of large extracellular vesicles from platelets (34%, p < 0.01), leukocytes (33%, p < 0.01), monocytes (60%, p < 0.01), endothelial cells (40%, p < 0.05), and syncytiotrophoblast cells (22%, p < 0.05) were observed. However, treatment with pravastatin significantly reduced the plasma levels of large extracellular vesicles from platelets (42%, p < 0.001), leukocytes (25%, p < 0.001), monocytes (61%, p < 0.001), endothelial cells (69%, p < 0.001), activated endothelial cells (55%, p < 0.001), and syncytiotrophoblast cells (44%, p < 0.001). Discussion: These results indicate that pravastatin reduces the levels of activated cell-derived membrane vesicles from the maternal vasculature, blood, and placental syncytiotrophoblast of women at high risk of term preeclampsia, suggesting that this statin may be beneficial in reducing endothelial dysfunction and pro-inflammatory and pro-coagulatory state characteristics of the disease. |
format | Online Article Text |
id | pubmed-10323224 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-103232242023-07-07 Pravastatin reduces plasma levels of extracellular vesicles in pregnancies at high risk of term preeclampsia Santoyo, Jean Michell Noguera, José Antonio Avilés, Francisco Hernández-Caselles, Trinidad de Paco-Matallana, Catalina Delgado, Juan Luis Cuevas, Santiago Llinás, M. Teresa Hernández, Isabel Front Pharmacol Pharmacology Introduction: Elevated plasma levels of extracellular vesicles have been associated with impaired placentation, angiogenesis imbalance, intravascular inflammation, and endothelial dysfunction in women with preeclampsia, thus suggesting that circulating vesicles may be a good therapeutic target for the treatment of the disease. Recently, statins have been considered a potential treatment for the prevention of preeclampsia because of their pleiotropic effects, including the improvement of endothelial dysfunction and inhibition of inflammatory responses. However, the effects of these drugs on circulating vesicles concentration in women at risk of preeclampsia have not been established. Herein, we aimed to assess the effects of pravastatin on circulating extracellular vesicle generation in women at high risk of term preeclampsia. Methods: In a sample of 68 singleton pregnant women participating in the multicenter, double-blind, placebo-controlled STATIN trial (Nº EducraCT 2016-005206-19 ISRCTN), 35 women received a placebo and 33 women received a 20 mg/day dose of pravastatin for approximately 3 weeks (from 35 to 37 weeks of gestation until delivery). Large extracellular vesicles were characterized and quantified by flow cytometry using annexin V and cell-specific antibodies directed against platelet, endothelial, leukocyte, and syncytiotrophoblast cell surface markers. Results: In women who received the placebo, a significant increase in the plasma levels of large extracellular vesicles from platelets (34%, p < 0.01), leukocytes (33%, p < 0.01), monocytes (60%, p < 0.01), endothelial cells (40%, p < 0.05), and syncytiotrophoblast cells (22%, p < 0.05) were observed. However, treatment with pravastatin significantly reduced the plasma levels of large extracellular vesicles from platelets (42%, p < 0.001), leukocytes (25%, p < 0.001), monocytes (61%, p < 0.001), endothelial cells (69%, p < 0.001), activated endothelial cells (55%, p < 0.001), and syncytiotrophoblast cells (44%, p < 0.001). Discussion: These results indicate that pravastatin reduces the levels of activated cell-derived membrane vesicles from the maternal vasculature, blood, and placental syncytiotrophoblast of women at high risk of term preeclampsia, suggesting that this statin may be beneficial in reducing endothelial dysfunction and pro-inflammatory and pro-coagulatory state characteristics of the disease. Frontiers Media S.A. 2023-06-22 /pmc/articles/PMC10323224/ /pubmed/37426825 http://dx.doi.org/10.3389/fphar.2023.1166123 Text en Copyright © 2023 Santoyo, Noguera, Avilés, Hernández-Caselles, de Paco-Matallana, Delgado, Cuevas, Llinás and Hernández. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Santoyo, Jean Michell Noguera, José Antonio Avilés, Francisco Hernández-Caselles, Trinidad de Paco-Matallana, Catalina Delgado, Juan Luis Cuevas, Santiago Llinás, M. Teresa Hernández, Isabel Pravastatin reduces plasma levels of extracellular vesicles in pregnancies at high risk of term preeclampsia |
title | Pravastatin reduces plasma levels of extracellular vesicles in pregnancies at high risk of term preeclampsia |
title_full | Pravastatin reduces plasma levels of extracellular vesicles in pregnancies at high risk of term preeclampsia |
title_fullStr | Pravastatin reduces plasma levels of extracellular vesicles in pregnancies at high risk of term preeclampsia |
title_full_unstemmed | Pravastatin reduces plasma levels of extracellular vesicles in pregnancies at high risk of term preeclampsia |
title_short | Pravastatin reduces plasma levels of extracellular vesicles in pregnancies at high risk of term preeclampsia |
title_sort | pravastatin reduces plasma levels of extracellular vesicles in pregnancies at high risk of term preeclampsia |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10323224/ https://www.ncbi.nlm.nih.gov/pubmed/37426825 http://dx.doi.org/10.3389/fphar.2023.1166123 |
work_keys_str_mv | AT santoyojeanmichell pravastatinreducesplasmalevelsofextracellularvesiclesinpregnanciesathighriskoftermpreeclampsia AT noguerajoseantonio pravastatinreducesplasmalevelsofextracellularvesiclesinpregnanciesathighriskoftermpreeclampsia AT avilesfrancisco pravastatinreducesplasmalevelsofextracellularvesiclesinpregnanciesathighriskoftermpreeclampsia AT hernandezcasellestrinidad pravastatinreducesplasmalevelsofextracellularvesiclesinpregnanciesathighriskoftermpreeclampsia AT depacomatallanacatalina pravastatinreducesplasmalevelsofextracellularvesiclesinpregnanciesathighriskoftermpreeclampsia AT delgadojuanluis pravastatinreducesplasmalevelsofextracellularvesiclesinpregnanciesathighriskoftermpreeclampsia AT cuevassantiago pravastatinreducesplasmalevelsofextracellularvesiclesinpregnanciesathighriskoftermpreeclampsia AT llinasmteresa pravastatinreducesplasmalevelsofextracellularvesiclesinpregnanciesathighriskoftermpreeclampsia AT hernandezisabel pravastatinreducesplasmalevelsofextracellularvesiclesinpregnanciesathighriskoftermpreeclampsia |